Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Open accessAbstract
SOST variants that mimic therapeutic inhibition of sclerostin for osteoporosis are associated with higher risk of cardiovascular disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Methods are under development for applying MR to disease progression, which take into account issues such as index event bias.
“Methods are under development for applying MR to disease progression, 80 which take into account issues such as index event bias 81 .”
From Integrating genomics with biomarkers and therapeutic targets to invigorate cardiovascular drug development (2021) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 122 · Cited by 119
Research works printed but not linked: 2
- [24]UCB EVENITY (romosozumab) receives positive CHMP opinion for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture 2019 www.ucb.com/stories-media/Press-Releases/article/EVENITY-romosozumab-Receives-Positive-CHMP-Opinion-for-the-Treatment-of-Severe-Osteoporosis-in-Postmenopausal-Women-at-High-Risk-of-Fracture
- [72]McGregor TL Hunt KA Nioi P Mason D Ticau S Pelosi M Perry L Finer S Griffiths C MacArthur D Trembath RC Deep phenotyping of a healthy human HAO1 knockout informs therapeutic development for primary hyperoxaluria type 1 bioRxiv 2019 1 18 524256 [Preprint
- Authors
- Bovijn, J., Krebs, K., Chen, C.-Y., Boxall, R., Censin, J. C., Ferreira, T., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., Lin, K., Li, L., Chen, Z., Milani, L., Smith, G. D., Walters, R. G., Mägi, R., Neale, B. M., Lindgren, C. M., & Holmes, M. V.
- Affiliations
- Centre for Human Genetics (GB)
- University of Tartu (EE)
- Broad Institute (US)
- University of Oxford (GB)
- Peking University (CN)
- University of Bristol (GB)
- John Radcliffe Hospital (GB)
- Corresponding author
- Bovijn, Jonas
- Krebs, Kristi
- Chen, Chia-Yen
- Boxall, Ruth
- Walters, Robin G.
- Mägi, Reedik
- Neale, Benjamin M.
- Lindgren, Cecilia M.
- Holmes, Michael V.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-06-24
- Volume
- 12
- Issue
- 549
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC7116615
- OpenAlex
- W3035249131
- Cited by
- 119
- References
- 122
- Citations by year
- 2026: 17 · 2025: 20 · 2024: 12 · 2023: 22 · 2022: 16 · 2021: 24 · 2020: 8
- FWCI
- 3.42
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- Li Ka Shing Foundation
- Wellcome
- Medical Research Council
- British Heart Foundation
- Estonian Research Council
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- John Fell Fund, University of Oxford
- NIHR Oxford Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- sclerostin inhibition, romosozumab, cardiovascular safety, genetic variants, myocardial infarction, coronary revascularization, major adverse cardiovascular events, type 2 diabetes, systolic blood pressure, abdominal obesity, osteoporosis, fracture risk, bone metabolism
- MeSH terms
- Human Genetics, Humans, Osteoporosis, Bone Density, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
